Potential With Cabozantinib Plus Nivolumab in Advanced RCC

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, senior physician, instructor in medicine, Harvard Medical School, discusses the goals of the phase III CheckMate-9ER trial, which is evaluating cabozantinib combined with nivolumab in previously untreated patients with advanced or metastatic renal cell carcinoma (RCC).

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, senior physician, instructor in medicine, Harvard Medical School, discusses the goals of the phase III CheckMate-9ER trial, which is evaluating cabozantinib (Cabometyx) combined with nivolumab (Opdivo) in previously untreated patients with advanced or metastatic renal cell carcinoma (RCC).

There has been a revolution in RCC treatment over the last couple of years, starting with the immunotherapy combination of nivolumab and ipilimumab (Yervoy) in the CheckMate-214 trial. Cabozantinib is an intriguing multikinase inhibitor that has also demonstrated benefit in patients with both treatment-naïve and previously treated disease, McGregor says.

Building upon the activity with these types of agents in the frontline setting, the CheckMare-9ER trial is looking at the combination of cabozantinib and nivolumab compared with sunitinib (Sutent) to determine if the combination can improve response rates and outcomes in the frontline setting.